UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

Leukemia, 2018-02, Vol.32 (2), p.252-262

2018

Volltextzugriff (PDF)

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis

Bone marrow transplantation (Basingstoke), 2013-04, Vol.48 (4), p.557-561

2013

Volltextzugriff (PDF)

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

Leukemia, 2016-11, Vol.30 (11), p.2208-2213

2016

Volltextzugriff (PDF)

Genetic aberrations and survival in plasma cell leukemia

Leukemia, 2008-05, Vol.22 (5), p.1044-1052

2008

Volltextzugriff (PDF)

Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma

Leukemia, 2014-10, Vol.28 (10), p.2060-2065

2014

Volltextzugriff (PDF)

How to manage primary amyloidosis

Leukemia, 2012-02, Vol.26 (2), p.191-198

Gertz, M A

2012

Volltextzugriff (PDF)

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

Leukemia, 2007-09, Vol.21 (9), p.2035-2042

2007

Volltextzugriff (PDF)

Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Leukemia, 2010-11, Vol.24 (11), p.1934-1939

2010

Volltextzugriff (PDF)

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Leukemia, 2024-08, Vol.38 (8), p.1866-1866

2024

Volltextzugriff (PDF)

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Leukemia, 2021-12, Vol.35 (12), p.3604-3607

2021

Volltextzugriff (PDF)

Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center

Bone marrow transplantation (Basingstoke), 2013-10, Vol.48 (10), p.1302-1307

2013

Volltextzugriff (PDF)

Second auto-SCT for treatment of relapsed multiple myeloma

Bone marrow transplantation (Basingstoke), 2013-04, Vol.48 (4), p.568-573

2013

Volltextzugriff (PDF)

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

Leukemia, 2016-03, Vol.30 (3), p.633-639

2016

Volltextzugriff (PDF)

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

Blood cancer journal (New York), 2023-05, Vol.13 (1), p.91-91

2023

Volltextzugriff (PDF)

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma

Blood cancer journal (New York), 2017-09, Vol.7 (9), p.e600-e600

2017

Volltextzugriff (PDF)

Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

Leukemia, 2006-11, Vol.20 (11), p.2034-2040

2006

Volltextzugriff (PDF)

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

Leukemia, 2007-03, Vol.21 (3), p.529-534

2007

Volltextzugriff (PDF)

Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and or transplant ineligible patients with multiple myeloma: a meta-analysis

Leukemia, 2011-04, Vol.25 (4), p.689-696

2011

Volltextzugriff (PDF)

Thalidomide as initial therapy for early-stage myeloma

Leukemia, 2003-04, Vol.17 (4), p.775-779

2003

Volltextzugriff (PDF)

Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma

Bone marrow transplantation (Basingstoke), 2009-04, Vol.43 (8), p.619-625

2009

Volltextzugriff (PDF)

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience

Blood cancer journal (New York), 2021-12, Vol.11 (12), p.196-196, Article 196

2021

Volltextzugriff (PDF)

Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations

Leukemia, 2006-05, Vol.20 (5), p.807-813

2006

Volltextzugriff (PDF)

Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival

Bone marrow transplantation (Basingstoke), 2017-08, Vol.52 (8), p.1126-1132

2017

Volltextzugriff (PDF)

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

Leukemia, 2013-01, Vol.27 (1), p.220-225

2013

Volltextzugriff (PDF)

Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma

Bone marrow transplantation (Basingstoke), 2010-09, Vol.45 (9), p.1396-1403

2010

Volltextzugriff (PDF)

1 – 25 von 2.123

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.845)
Mit Volltextzugriff
(1.869)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(2.093)
Deutsch
(18)
Französisch
(10)
Japanisch
(2)
Spanisch
(1)
Dänisch
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.321)
Life Sciences & Biomedicine
(1.090)
Humans
(945)
Male
(594)
Female
(591)
Middle Aged
(470)
Biological And Medical Sciences
(450)
Aged
(427)
Medical Sciences
(423)
Hematology
(355)
Adult
(329)
Oncology
(272)
Technology
(225)
Computer Science
(206)
Computer Science, Information Systems
(186)
Aged, 80 And Over
(170)
Treatment Outcome
(165)
Multiple Myeloma
(159)
Retrospective Studies
(158)
Prognosis
(142)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(240)
Journal Of Clinical Oncology
(90)
Leukemia
(78)
Bone Marrow Transplantation
(69)
American Journal Of Hematology
(46)
Mayo Clinic Proceedings
(45)
Blood Cancer Journal
(29)
Biology Of Blood And Marrow Transplantation
(28)
Circulation
(27)
British Journal Of Haematology
(24)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

Genetic aberrations and survival in plasma cell leukemia

Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma

How to manage primary amyloidosis

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center

Second auto-SCT for treatment of relapsed multiple myeloma

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma

Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and or transplant ineligible patients with multiple myeloma: a meta-analysis

Thalidomide as initial therapy for early-stage myeloma

Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience

Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations

Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma

Suchergebnisse filtern